S&P 500 5,278.40 +0.45% NASDAQ 16,755.02 +0.67% DOW JONES 38,886.57 +0.32% RUSSELL 2000 2,084.45 +0.15% VIX 13.42 -1.52% GOLD 2,348.30 +0.21% OIL (WTI) 78.62 +0.18% US 10Y 4.28% -0.04%
All articles Labor Market

Ironwood Pharmaceuticals Names Jeffrey Silber Chief Medical Officer

Ryan Ashford 1 min read  ·  July 14, 2026
Ironwood Pharmaceuticals Names Jeffrey Silber Chief Medical Officer

(RTTNews) – Ironwood Pharmaceuticals, Inc. (IRWD) announced the retirement of Chief Medical Officer and Head of Research and Drug Development Michael Shetzline and the appointment of Jeffrey Silber as his successor. Silber will oversee Research and Drug Development,
Regulatory Affairs and Medical Affairs. Silber joins Ironwood on July 20, 2026. Shetzline will remain an advisor to the company. Silber joins Ironwood from Vedanta Biosciences where he was Chief Medical Officer since 2020.

The company also announced that the confirmatory Phase 3 STARS-2 trial of apraglutide
in patients with short bowel syndrome with intestinal failure was initiated in June and is now actively recruiting patients.

In pre-market trading on NasdaqGS, Ironwood shares are down 1.23 percent to $4.1583.

For More Such Health News, visit rttnews.com.

Written by

Ryan Ashford

Senior markets analyst · Podcast host

Ryan covers global equity markets, interest rate cycles, and the macro forces reshaping capital flows. Before Eagle One, he spent a decade at institutional trading desks writing cross-asset research for fund managers. His work translates complex monetary signals into clear investor decisions.

Eagle One Intelligence

The edge serious investors read.

Macro shifts, market structure, and the ideas worth tracking — straight to your inbox.

Note. For informational purposes only. Not financial advice. Past performance does not guarantee future results.

Keep reading